

Klíčové je zhodnocení celkového stavu pacienta, případně s využitím nástrojů k predikci pooperační morbidita a mortality a zvažení dalších alternativ operace, jako jsou aktivní sledování nebo

termální ablace tumoru. Týmové rozhodování a spolupráce jsou klíčem ke skutečné individualizaci léčby a dosažení optimálního onkologického výsledku.

LITERATURA

1. Brierley J, Gospodarowitz M, Wittekind C, et al. Union for International Cancer Control (UICC). TNM Classification of Malignant Tumours. 8th ed. Oxford, UK: John Wiley & Sons, Inc. 2017; 241.
2. Tomaszewski JJ, Uzzo RG, Kutikov A, et al. Assessing the burden of complications after surgery for clinically localized kidney cancer by age and comorbidity status. *Urology*. 2014; 83(4): 843–849.
3. Ball MW, Bezerra SM, Gorin MA, et al. Grade heterogeneity in small renal masses: potential implications for renal mass biopsy. *J Urol*. 2015; 193(1): 36–40.
4. Thompson RH, Hill JR, Babayev Y, et al. Metastatic renal cell carcinoma risk according to tumor size. *J Urol*. 2009; 182(1): 41–45.
5. Patel HD, Kates M, Pierorazio PM, et al. Comorbidities and causes of death in the management of localized T1a kidney cancer. *Int J Urol*. 2014; 21(11): 1086–1092.
6. Ljungberg B, Albiges L, Bedke J, et al. EAU Guidelines on Renal Cell Carcinoma. In: EAU Guidelines. Edition presented at the EAU Annual Congress Milan 2021. Arnhem, The Netherlands: EAU Guidelines Office. 2021; 84.
7. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. *J Urol*. 2009; 182(4): 1271–1279.
8. Hora M, Eret V, Stránský P, et al. Laparoskopická resekce tumorů ledviny. *Ces Urol*. 2015; 19(2): 103–105.
9. Študent V, Hartmann I, Vidlář A, Grepl M. Roboticky asistovaná resekce ledviny pro tumor. *Ces Urol*. 2016; 20(1): 13–15.
10. Korc-Grodzicki B, Downey RJ, Shahrokni A et al. Surgical considerations in older adults with cancer. *J Clin Oncol*. 2014; 32(24): 2647–2653.
11. Sun M, Becker A, Tian Z, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. *Eur Urol*. 2014; 65(1): 235–241.
12. Tang DH, Nawlo J, Chipollini J, et al. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach? *Clin Genitourin Cancer*. 2017; 15(6): 696–703.
13. Kim SP, Thompson RH, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. *J Urol*. 2012; 188(1): 51–57.
14. Shuch B, Hanley J, Lai J, et al. Overall survival advantage with partial nephrectomy: a bias of observational data? *Cancer*. 2013; 119(16): 2981–2989.
15. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. *Lancet Oncol*. 2006; 7(9): 735–740.
16. Huang WC, Atoria CL, Bjurlin M, et al. Management of Small Kidney Cancers in the New Millennium: Contemporary Trends and Outcomes in a Population-Based Cohort. *JAMA Surg*. 2015; 150(7): 664–672.
17. Shah PH, Alom MA, Leibovich BC, et al. The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass. *J Urol*. 2018; 200(5): 981–988.
18. Matějková M, Kočárek J. Rizika a komplikace robotické resekce ledviny u pacientů starších 65 let. *Geriatr Gerontol* 2019; 8(2): 59–63.
19. Poletajew S, Zapała P, Kopczyński B, et al. Surgical treatment for renal masses in the elderly: analysis of oncological, surgical and functional outcomes. *Int Braz J Urol*. 2019; 45(3): 531–540.